4 226

Cited 9 times in

Active tuberculosis risk with tumor necrosis factor inhibitors after treating latent tuberculosis.

DC FieldValueLanguage
dc.contributor.author송정식-
dc.contributor.author이상원-
dc.contributor.author이수곤-
dc.contributor.author박용범-
dc.contributor.author송영구-
dc.date.accessioned2015-01-06T16:34:48Z-
dc.date.available2015-01-06T16:34:48Z-
dc.date.issued2014-
dc.identifier.issn1076-1608-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/98370-
dc.description.abstractBACKGROUND: Active tuberculosis (TB) risk increases during anti-tumor necrosis factor (TNF) therapy; therefore, latent TB infection (LTBI) screening is recommended in potential TNF inhibitor users. It is unclear whether anti-TNF therapy increases the risk of active TB infection even after standard LTBI treatment. OBJECTIVE: The objective of this study was to compare the risk of active TB development in LTBI-positive versus LBTI-negative TNF inhibitor users following the current national LTBI treatment guidelines for LTBI. METHODS: We retrospectively studied 949 TNF inhibitor users with immune-mediated inflammatory diseases from 2005 to 2012 at the Yonsei University Health System. We compared the incidence of active TB among LTBI-positive TNF inhibitor users treated according to national guidelines (n = 256) and LTBI-negative TNF inhibitor users (n = 521), using Poisson regression. RESULTS: The active TB incidence was 1107 per 100,000 patient-years in LTBI-positive TNF inhibitor users who received standard LTBI treatment and 490 per 100,000 patient-years in LTBI-negative TNF inhibitor users. Analysis showed that despite this numerical trend active TB risk was not statistically significantly elevated in LTBI-positive versus LTBI-negative TNF inhibitor users (incidence risk ratio, 2.15; P = 0.24; 95% confidence interval, 0.6-7.7). CONCLUSIONS: This study demonstrated no statistically significantly increased risk of active TB in LTBI-positive TNF inhibitor users who received standard LTBI treatment compared with LTBI-negative TNF inhibitor users.-
dc.description.statementOfResponsibilityopen-
dc.format.extent68~73-
dc.relation.isPartOfJCR-JOURNAL OF CLINICAL RHEUMATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAntirheumatic Agents/adverse effects*-
dc.subject.MESHAntirheumatic Agents/therapeutic use*-
dc.subject.MESHAntitubercular Agents/therapeutic use*-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHIncidence-
dc.subject.MESHLatent Tuberculosis/drug therapy*-
dc.subject.MESHLatent Tuberculosis/microbiology-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMycobacterium tuberculosis-
dc.subject.MESHRegression Analysis-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHRheumatic Diseases/drug therapy*-
dc.subject.MESHRisk Factors-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHTuberculosis/epidemiology*-
dc.subject.MESHTuberculosis/microbiology-
dc.subject.MESHTumor Necrosis Factor-alpha/antagonists & inhibitors*-
dc.titleActive tuberculosis risk with tumor necrosis factor inhibitors after treating latent tuberculosis.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorMinkyung Kwon-
dc.contributor.googleauthorMindong Sung-
dc.contributor.googleauthorYong-Jin Kwon-
dc.contributor.googleauthorYoung Goo Song-
dc.contributor.googleauthorSang-Won Lee-
dc.contributor.googleauthorMin-Chan Park-
dc.contributor.googleauthorYong-Beom Park-
dc.contributor.googleauthorSoo-Kon Lee-
dc.contributor.googleauthorJason Jungsik Song-
dc.identifier.doi10.1097/RHU.0000000000000074-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA02057-
dc.contributor.localIdA02889-
dc.contributor.localIdA01579-
dc.contributor.localIdA02037-
dc.contributor.localIdA02824-
dc.relation.journalcodeJ01215-
dc.identifier.eissn1536-7355-
dc.identifier.pmid24561408-
dc.identifier.urlhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00124743-201403000-00002&LSLINK=80&D=ovft-
dc.contributor.alternativeNameSong, Jung Sik-
dc.contributor.alternativeNameLee, Sang Won-
dc.contributor.alternativeNameLee, Soo Kon-
dc.contributor.alternativeNamePark, Yong Beom-
dc.contributor.alternativeNameSong, Young Goo-
dc.contributor.affiliatedAuthorSong, Jung Sik-
dc.contributor.affiliatedAuthorLee, Soo Kon-
dc.contributor.affiliatedAuthorPark, Yong Beom-
dc.contributor.affiliatedAuthorSong, Young Goo-
dc.contributor.affiliatedAuthorLee, Sang Won-
dc.rights.accessRightsfree-
dc.citation.volume20-
dc.citation.number2-
dc.citation.startPage68-
dc.citation.endPage73-
dc.identifier.bibliographicCitationJCR-JOURNAL OF CLINICAL RHEUMATOLOGY, Vol.20(2) : 68-73, 2014-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.